Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of Asthmatic Patient

Summary

Participation Requirements

Description

Patients will be openly labeled in one of the following group 15 patients with severe asthma, without oral corticosteroids treatment., 6 patients with mild to moderate asthma without treatment, 21 controlled samples from smooth muscle cells of non-asthmatic deceased donor Bronchial endoscopy with br...

Patients will be openly labeled in one of the following group 15 patients with severe asthma, without oral corticosteroids treatment., 6 patients with mild to moderate asthma without treatment, 21 controlled samples from smooth muscle cells of non-asthmatic deceased donor Bronchial endoscopy with bronchial biopsies will be assessed in all asthmatic patients, Control samples will be obtained from tracheobronchial rings of cadaveric donor. Expression and activity of Rac1 in airway smooth muscle will be determined by immuno-staining on paraffinised biopsies. Patients will undergo two study visits (D0: inclusion visit, D15: exploratory visit) and one phone call at D21. Inclusion Visit (D0): Signature of the Informed consent, Medical History, Clinical examination, Pulmonary Function Test, Blood samples for fibroscopy safety, ACT (Asthma Control Test), ACQ (Asthma Control Questionnaire), AQLQ (Asthma Quality of Life Questionnaire), Morisky questionnaire Exploratory visit (D15) Clinical examination, Bronchial endoscopy with biopsies Adverse event Phone Call (D21) - Adverse event Recruitment will last 4 years.

Tracking Information